Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III multicenter randomized open-label trial of semaglutide injection vs Novo Nordisk Wegovy (诺和盈) in obese patients
CTR20250556Phase 3Active
- Sponsor
- Shandong New Era Pharmaceutical
- Start
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in obesity, sponsored by Shandong New Era Pharmaceutical. Started Sep 2025; status: active.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on CTR20250556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250556.